Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients

Blood

Volumn 92, Issue 1, 1998, Pages 68-75

  Hellström Lindberg, Eva ^a   Ahlgren, Tomas ^b   Beguin, Yves ^b   Carlsson, Magnus ^b   Carneskog, Jan ^b   Dahl, Inger Marie ^b   Dybedal, Ingunn ^b   Grimfors, Gunnar ^b   Kanter Lewensohn, Lena ^b   Linder, Olle ^b   Luthman, Michaela ^b   Löfvenberg, Eva ^b   Nilsson Ehle, Herman ^b   Samuelsson, Jan ^b   Tangen, Jon Magnus ^b   Winqvist, Ingemar ^b   Öberg, Gunnar ^b   Österborg, Anders ^b   Öst, Åke ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN BETA; FERRITIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBOCYTOPENIA;

EID: 2642686614     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.1.68.413k23_68_75     Document Type: Article

References (31)

1. Greenberg PL: The myelodysplastic syndromes, in Hoffman R, Benz E, Shattil S, Furie B, Cohen H (eds): Hematology: Basic Principles and Practice (ed 2). New York, NY, Churchill Livingstone, 1994, p 1098
2. Greenberg PL, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079, 1997
3. Negrin R, Haeuber D, Nagler A, Kobayashi Y, Sklar J, Donlon T, Vincent M, Greenberg P: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36, 1990
4. Yoshida Y, Hirashima K, Asano S, Takaku F: A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78:378, 1991
5. Greenberg P, Taylor K, Larson R, Koeffler P, Negrin R, Saba H, Ganser A, Jakubowski A, Gabrilove J, Mufti G, Cruz J, Hammond W, Broudy V, Langley GR, Keating A, Vardiman J, Lamborn K, Brown S: Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood 82:196a, 1993 (suppl 1)
6. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman W, McCredie K, Trujillo J. Broxmeyer H, Henney C and Gutterman J: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545, 1987
7. Shuster MW. Larson RA, Thompson JA, Coiffier B. Bennett JM, Israel RJ for the Shering-Plough/Sandoz MDS Study Group: Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): Results of a multi-center randomized controlled trial. Blood 76:318a, 1990
8. Shuster MW, Thompson JA, Larson RA, Dugan et al: Randomized phase II study of recombinant granulocyte-macrophage colony-stimulating factor (RGM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS). Blood 86:338a, 1995
9. Bessho M, Jinnai I, Matsuda A, Saito M, Hirashima K: Improvement of anaemia by recombinant eryhtropoietin in patients with myelodysplastic syndromes and aplastic anaemia. Int J Cell Cloning 8:445, 1990
10. Hellström E, Birgegård G, Lockner D, Wide L, Helmers C, Öst Å: Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 47:355, 1991
11. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L: The use of r-HUEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831, 1995
12. Hellström Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes. An analysis of 205 patients in 17 studies. Br J Haematol 89:67, 1995
13. Amano Y, Koike K, Nakahata T: Stem cell factor enhances the growth of primitive erythroid progenitors to a greater extent than interleukin 3 in patients with aplastic anemia. Br J Haematol 85:663, 1993
14. Backx B, Breeders L, Löwenberg B: Kit ligand improves in vitro erythropoiesis in myelodysplastic syndromes. Blood 80:1213, 1992
15. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg P: Treatment of the anaemia of myelodysplastic syndromes using human granulocyte-CSF in combination with erythropoietin. Blood 82:737, 1993
16. Hellström-Lindberg E, Birgegård G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I, Öst Å: A combination of granulocyte-colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221, 1993
17. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J. Krantz S, Greenberg P: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy. Blood 87:4076, 1996
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR. Sultan C, The French-American-British (FAB) Group: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
19. Wide L, Bengtsson C, Birgegård G: Circadian rythm of human serum erythropoietin. Br J Haematol 51:189, 1989
20. Beguin Y, Clemons G, Pootrakul P, Fillet G: Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81:1067, 1993
21. Hellström-Lindberg E, Robèrt KH, Gahrton G, Forsblom AM, Lindberg G, Kock Y, Öst Å: A predictive model for the clinical response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukemia. Br J Haematol 81:503, 1992
22. Miller KB, Kyungman K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA. O'Connell MJ: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study. Ann Hematol 65:162, 1992
23. Ganser A, Maurer A, Contzen C, Seipelt G, Ottmann OG, Schadeck-Gressel C, Kolbe K, Haas R, Zander C, Reutzel R, Hoelzer D: Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-transretinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Hematol 72:237, 1996
24. Imamura M, Kobayashi M, Kobayashi S, Yoshida K, Mikuni C, Ishikawa Y, Matsumoto S, Sakamaki S, Niitsu Y, Hinoda Y, Yachi A, Kudoh T, Chiba S, Kasai M, Oka T, Okuno A, Maekawa T, Sakurada K, Miyazaki T: Failure of combination therapy with granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes. Ann Hematol 68:163, 1994
25. Musto P, Falvone A, Carotenuto M: Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: A real improvement with respect to EPO alone? Blood 84:1687, 1994
26. Cazzola M, Mercuriali F, Brugnara C: Use of recombinant human erythropoietin outside the setting of uremia. Blood 89:4248, 1997
27. Stenke L, Wallvik J, Celsing F, Hast R: Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7:1324, 1993
28. Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Öst Å, Greenberg P: Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: Proposal for a predictive model. Br J Haematol 99:344, 1997
29. May SJ, Smith SA, Jacobs A, Williams A, Bailey-Wood R: The myelodysplastic syndromes: Analysis of laboratory characteristics in relation to the FAB classifiacation. Br J Haematol 59:311, 1985
30. Hellström-Lindberg E, Kanter-Lewensohn L, Öst Å: Morphological changes and apoptosis in bone marrow from patients treated with granulocyte-CSF and erythropoietin. Leuk Res 21:415, 1997
31. Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N: Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters. Leukemia 8:151, 1994